Amylyx Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)
During the three months ended September 30, 2026, no officers or directors of the Company (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(c) of Regulation S-K of the Exchange Act, except as described below:
Camille L. Bedrosian, M.D., our Chief Medical Officer, adopted a new Rule 10b5-1 trading plan on September 23, 2026, which is scheduled to expire on December 31, 2027. The aggregate number of shares of our common stock authorized to be sold under this new arrangement is 55,000. Dr. Bedrosian entered into a lock-up agreement in connection with the Offering, pursuant to which she is not permitted to transfer, sell or otherwise dispose of securities under such plan during the lock-up period.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.